The P1Vital PReDicT study is a clinical trial testing a software (the PReDicT Test) that helps to more quickly predict whether a patient is responding to antidepressant medication. Current approaches to detecting treatment response (using questionnaire measures available to GPs) take between 4 to 6 weeks and the PReDicT Test holds the potential to reduce this to 1 week. More information about the PReDicT Test technology is available here. Patient recruitment started in  July 2016 and the study ends in 2018.

The study is an international trial taking place in five European countries (UK, France, Germany, Netherlands and Spain), co-funded by the European Commission’s Horizon 2020 EU Framework Programme for Research and Innovation. The trial is a collaboration between industry, healthcare and academia and a list of partners is given below. The trial is being run within primary care, and GPs (or an equivalent consulting clinician in the European countries) will invite patients to join the study if they are being prescribed an antidepressant (some exceptions apply, for example patients with very complex mental health needs; the study is being implemented in 26 GP practices in the UK). The trial will compare the outcomes of patients treated using the PReDicT Test (group 1) to those receiving treatment as usual (group 2). The main outcome tested will be whether or not more patients show a response to treatment after 8 weeks using the PReDicT Test than without it, and to compare the extent of improvement in patients in both groups. You can read more about the study here. Patients are currently being recruited in the UK, and the other European sites will soon begin recruitment. The study will be completed in late 2018.

As well as testing whether the PReDicT Test improves outcomes, the study will examine cost effectiveness of its use (carried out by research partners in Oxford), and its acceptability amongst patients and clinicians as part of care (carried out by MindTech). The study will provide valuable evidence of its potential use in primary care treatment for depression.

Partners involved in the study are:

· P1Vital Products Limited

· University of Oxford, Health Economics Research Centre

· University of Nottingham, MindTech

· Hospital Sainte-Anne, Paris Descartes University

· Universitätsklinikum Würzburg

· Department of Psychiatry, Psychosomatic Medicine and Psychotherapy at University Hospital Frankfurt

· Parc de Salut Mar, and Hospital del Mar Medical Research Institute (IMIM), Barcelona; Biomedical Research Networking Center for Mental Health Network (CIBERSAM)

· VU University Medical Centre Amsterdam

· Universitair Centrum Psychiatrie (UMCG), Netherlands and GGZ ingest, Netherlands

Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.

Further information: visit the PReDicT study website